Patrick Vermersch (University of Lille and CHU Lille, Lille, France) shares promising findings and expert insight from the phase 3 study of masitinib for the treatment of progressive multiple sclerosis (ClinicalTrials.gov identifier: NCT01433497). This discussion was based on his MSVirtual2020 presentation: FC04.01 Masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis: Results from phase 3 study AB07002.
1. Tell us about the aims, design and major key findings of the AB07002 study. (0:06)
2. What is the clinical significance of these findings and what future studies are planned? (5:01)
See also the 1st part of this interview here.
Disclosures: Dr Vermersch reports receiving honoraria and consulting fees from Biogen, Celgene, Novartis, Sanofi-Genzyme, Merck, Roche and Teva; he also receives research support from Novartis, Roche and Sanofi-Genzyme.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.
Share this Video
Related Videos In Multiple Sclerosis
Bernhard Hemmer, ECTRIMS 2021: Phase 3 Antelope Study Results Investigating Natalizumab Biosimilar PB006 in RMS
touchNEUROLOGY met up with Prof. Bernhard Hemmer (TUM-Klinikum rechts der Isar, Munich, Germany) to discuss the primary data from the phase III Antelope study, investigating proposed natalizumab biosimilar PB006 in relapsing remitting multiple sclerosis. The abstract entitled: ‘Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: primary […]
Le Hanh Hua, ECTRIMS 2021: Hot Topics in Multiple Sclerosis
touchNEUROLOGY joins Dr Le Hanh Hua (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) to discuss the hot topics in the field of multiple sclerosis. The abstract entitled: ‘Safety and efficacy of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study’ was […]
Le Hanh Hua, ECTRIMS 2021: Siponimod’s Efficacy on Secondary Progressive MS – Post-hoc Analysis of the EXPAND Study
It was a pleasure to meet with Dr Le Hanh Hua (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) to discuss the use of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study. The abstract entitled: ‘Safety and efficacy of siponimod in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!